| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 06/14/2011 | US7960396 Inhibitors of Bruton's tyrosine kinase |
| 06/14/2011 | US7960395 5,7-disubstituted thiazolo[4,5-d]pyrimidines for the selective inhibition of chemokine receptors |
| 06/14/2011 | US7960394 3,8-dimethyl-2-[4-(3-piperidin-1-ylpropoxy)phenyl]-4(3H)-quinazolinone; 6-chloro-3-methyl-2-[4-(3-piperidin-1-ylpropoxy)phenyl]pyrido[3,4-d]-pyrimidin-4(3H)-one; 2-[4-(1-cyclopentyl-4-piperidinyloxy)phenyl]-3-methylpyrido[2,3-d]-pyrimidin-4(3H)-one; treats metabolic, nervous system, vascular disorders |
| 06/14/2011 | US7960393 Pyrimidine derivatives useful for the treatment of diseases mediated by CRTH2 |
| 06/14/2011 | US7960392 Nitrogen-containing heterocyclic compounds |
| 06/14/2011 | US7960389 4(phenyl-piperazinyl-methyl) benzamide derivatives and their use for the treatment of pain or gastrointestinal disorders |
| 06/14/2011 | US7960388 3-(imidazolyl)-pyrazolo[3,4-b]pyridines |
| 06/14/2011 | US7960387 2-(3-phenyl-2-piperazinyl-3,4-dihydroquinazolin-4-yl)acetic acids as antiviral agents, especially against cytomegaloviruses |
| 06/14/2011 | US7960386 Pyridin-2-one compounds and their use as modulators of the dopamine D3 receptor |
| 06/14/2011 | US7960385 Guanidine-containing compounds useful as muscarinic receptor antagonists |
| 06/14/2011 | US7960384 Dipeptidyl peptidase inhibitors |
| 06/14/2011 | US7960383 Pyridazin-3(2H)-one derivatives and their use as PDE4 inhibitors |
| 06/14/2011 | US7960382 Compounds and their use related to compositions for treating disease |
| 06/14/2011 | US7960381 Substituted gamma lactams as therapeutic agents |
| 06/14/2011 | US7960380 Non-anilinic derivatives of isothiazol-3(2H)-one 1,1-dioxides as liver X receptor modulators |
| 06/14/2011 | US7960379 Therapeutic compounds |
| 06/14/2011 | US7960378 Therapeutic compounds |
| 06/14/2011 | US7960377 Substituted pyridoxazines |
| 06/14/2011 | US7960376 Benzo-fused heterocycles |
| 06/14/2011 | US7960375 new 8-chloro-2,3-benzodiazepine derivatives of the general formula (I), wherein R stands for a lower alkyl group or a group of the general formula NH R', wherein R' stands for a lower alkyl or a lower cycloalkyl group), and pharmaceutically acceptable acid addition salts thereof for intermediates. |
| 06/14/2011 | US7960374 e.g. 2,5-methylene-9-(phenylsulfonyl)-1,2,3,4,5,9-hexahydro[1,5]oxazocino[3,2-e]indole; serotonin receptors antagonist or partial agonist; metabolic diseases, e.g. obesity, insulin resisitance, type 2 diabetes, eating disorders; antidepressant, anxiolytic agent; cosmetics |
| 06/14/2011 | US7960373 2-alkoxy-3,4,5-trihydroxyalkylamide-benzothiazepines preparation thereof, compositions containing them and use thereof |
| 06/14/2011 | US7960372 Bivalent Smac mimetics and the uses thereof |
| 06/14/2011 | US7960370 Type A gelatin capsule containing PUFA in free acid form |
| 06/14/2011 | US7960369 Receptor function regulator |
| 06/14/2011 | US7960368 Bismethylene-17A carbolactones and related uses |
| 06/14/2011 | US7960367 Pregnane steroids and their use in the treatment of CNS disorders |
| 06/14/2011 | US7960366 Substituted tetracycline compounds as synergistic antifungal agents |
| 06/14/2011 | US7960360 Antisense guanidinium peptide nucleic acid (GPNA) oligonucleotides as antitumor agents |
| 06/14/2011 | US7960359 Methods and compositions involving miRNA and miRNA inhibitor molecules |
| 06/14/2011 | US7960358 Antisense modulation of stearoyl-CoA desaturase expression |
| 06/14/2011 | US7960356 Induces production of a cytokine or activates dendritic cells, natural killer cells and monocytes; autoimmune disorders; vaccine |
| 06/14/2011 | US7960353 Novobiocin analogues as neuroprotective agents and in the treatment of autoimmune disorders |
| 06/14/2011 | US7960352 Anticancer agent saxifragifolin D, saxifragifolin B |
| 06/14/2011 | US7960351 Method for producing pectin hydrolysis products |
| 06/14/2011 | US7960350 Comprises N-alpha-acetyl-L-histidine; kits; droppers |
| 06/14/2011 | US7960347 Matrix protein compositions for induction of apoptosis |
| 06/14/2011 | US7960341 Methods and compositions for treating polycystic ovary syndrome |
| 06/14/2011 | US7960138 Method for prognosing response to cancer therapy with 5, 10, 15, 20-tetrakis (carboxyphenyl) porphine |
| 06/14/2011 | US7960118 EGFR mutations |
| 06/14/2011 | US7960102 Regulated aptamer therapeutics |
| 06/14/2011 | US7959958 Cooling compounds |
| 06/14/2011 | US7959955 Antipyrotic formulation for the treatment of epidermal burns |
| 06/14/2011 | US7959951 Nitric oxide and its biomedical significance |
| 06/14/2011 | US7959948 Pharmaceutical composition of quetiapine fumarate |
| 06/14/2011 | US7959947 Film coating |
| 06/14/2011 | US7959946 Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative |
| 06/14/2011 | US7959945 Bosentan; excipients, filler, lubricant, disintegrant, acidifying agent, flavouring, sweetening; endothelin receptor inhibitor; pulmonary arterial hypertension |
| 06/14/2011 | US7959944 Cognition activators; antiaging agent;veterinary medicine |
| 06/14/2011 | US7959913 Applying a mixture of a retinoid, antimicotic compound that enhances conversion of retinoid to retinoic acid and prevents the retinoic acid degradation (bifonazole, climbazole), fatty alcohol and/or fatty acid, and cosmetic vehicle to treat the skin for wrinkles, psoriasis, age spots or discoloration. |
| 06/14/2011 | US7959907 Method of treating cancer by combination therapy using TNF and alpha-galactosylceramide |
| 06/14/2011 | US7959905 Tamanu oil products |
| 06/14/2011 | US7959904 Etching nail surface; applying fungicide |
| 06/14/2011 | US7959903 Comprises mineral nanopigment based on titanium dioxide; for protecting against ultraviolet radiation |
| 06/14/2011 | CA2643177C Multi-cyclic compounds for treating cancer |
| 06/14/2011 | CA2623296C Novel solubility enhancer and use thereof |
| 06/14/2011 | CA2619897C Novel tricyclic compounds, preparation method and pharmaceutical compositions containing same |
| 06/14/2011 | CA2616910C Non-steroidal androgen receptor modulators, preparation process, pharmaceutical composition and use thereof |
| 06/14/2011 | CA2614631C Pharmaceutical compositions based on anticholinergics and corticosteroids in the form of an inhalable solution or suspension |
| 06/14/2011 | CA2601808C Use of macelignan for treatment of brain diseases |
| 06/14/2011 | CA2600727C Thiadiazole substituted coumarin derivatives and their use as leukotriene biosynthesis inhibitor |
| 06/14/2011 | CA2591054C Methamphetamine derivatives and conjugates for immunoassay |
| 06/14/2011 | CA2566301C Novel use of peptide compounds for treating essential tremor and other tremor syndromes |
| 06/14/2011 | CA2564442C 2-pyridyl substituted imidazoles as alk5 and/or alk4 inhibitors |
| 06/14/2011 | CA2556489C Use of folates for the prevention and treatment of vascular diseases |
| 06/14/2011 | CA2534921C Aminotriazole compounds useful as inhibitors of protein kinases |
| 06/14/2011 | CA2527657C Modified fluorinated nucleoside analogues |
| 06/14/2011 | CA2520586C Novel ido inhibitors and methods of use |
| 06/14/2011 | CA2517450C 7-imino derivatives of camptothecin having antitumor activity |
| 06/14/2011 | CA2512987C 17-carbamoyloxy cortisol derivatives as selective glucocorticoid receptor modulators |
| 06/14/2011 | CA2507774C Avermectin b1 and avermectin b1 monosaccharide derivatives having an alkoxymethyl substituent in the 4"- or 4'-position |
| 06/14/2011 | CA2503183C Salmeterol superfine formulation |
| 06/14/2011 | CA2496676C 3,4-di-substituted cyclobutene-1,2-diones as cxc-chemokine receptor ligands |
| 06/14/2011 | CA2495661C Inhibition of phosphoinositide 3-kinase beta |
| 06/14/2011 | CA2495463C Extended release composition containing tramadol |
| 06/14/2011 | CA2494962C Tyrosine kinase inhibitors |
| 06/14/2011 | CA2494061C Protein tyrosine kinase inhibitors |
| 06/14/2011 | CA2492876C 1-phenyl-2-dimethylaminomethylcyclohexane compounds for therapy of depressive symptoms, pain, and incontinence |
| 06/14/2011 | CA2492378C Modified amino acid for the inhibition of platelet aggregation |
| 06/14/2011 | CA2492274C Flavonoid compounds as therapeutics antioxidants |
| 06/14/2011 | CA2484183C Methods and compositions for treating ectoparasite infestation |
| 06/14/2011 | CA2484080C Novel flavanoids and chalcones as chemotherapeutic, chemopreventive, and antiangiogenic agents |
| 06/14/2011 | CA2481763C Piperazine benzothiazoles as agents for the treatment of cerebral ischemic disorders or cns disorders |
| 06/14/2011 | CA2480987C Natural products and derivatives thereof for protection against neurodegenerative diseases |
| 06/14/2011 | CA2480678C New heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them and their use in medicine |
| 06/14/2011 | CA2478232C Heterocyclic amide derivatives as cytokine inhibitors |
| 06/14/2011 | CA2477144C Orally administrable composition for the photoprotection of the skin |
| 06/14/2011 | CA2476127C New pharmaceutical compositions based on anticholinergics and egfr kinase inhibitors |
| 06/14/2011 | CA2473967C Thin film with non-self-aggregating uniform heterogeneity, process for their production and drug delivery systems made therefrom |
| 06/14/2011 | CA2473815C Aerosol formulation for inhalation containing a tiotropium salt |
| 06/14/2011 | CA2470037C Prodrugs to d-prolines |
| 06/14/2011 | CA2468704C Urea derivatives as angiogenesis inhibitors |
| 06/14/2011 | CA2465328C Piperidines |
| 06/14/2011 | CA2461614C Mixture of base-containing micronutrient substances |
| 06/14/2011 | CA2458267C Bifunctional chelating agent for actinium |
| 06/14/2011 | CA2456235C Heterocyclylarylsulphonamides |
| 06/14/2011 | CA2452752C Dye-azide compounds for dual phototherapy |
| 06/14/2011 | CA2452738C Gastric retention controlled drug delivery system |
| 06/14/2011 | CA2451859C Substituted 1-oxa-2,8-diaza-spiro[4,5]dec-2-ene derivatives as medicaments for the treatment of pain |
| 06/14/2011 | CA2445322C Use of the abc expression promoting agent pioglitazone for the treatment of arteriosclerosis obliterans |